CN113354679A - Preparation process of distearoyl phosphatidyl glycerol sodium - Google Patents
Preparation process of distearoyl phosphatidyl glycerol sodium Download PDFInfo
- Publication number
- CN113354679A CN113354679A CN202110754813.XA CN202110754813A CN113354679A CN 113354679 A CN113354679 A CN 113354679A CN 202110754813 A CN202110754813 A CN 202110754813A CN 113354679 A CN113354679 A CN 113354679A
- Authority
- CN
- China
- Prior art keywords
- reaction
- preparation
- benzyloxy
- sodium
- oxo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 title claims abstract description 21
- 239000011734 sodium Substances 0.000 title claims abstract description 16
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 16
- 238000006243 chemical reaction Methods 0.000 claims description 58
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 29
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical group OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 11
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 10
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 claims description 10
- 150000007530 organic bases Chemical class 0.000 claims description 9
- -1 5- (benzyloxy) -2- (4-nitro-phenoxy) -2-oxo-1, 3, 2-dioxaphosphorinane Chemical compound 0.000 claims description 8
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 8
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 8
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 5
- 238000007142 ring opening reaction Methods 0.000 claims description 5
- UDIPIOHLDFSMLR-UHFFFAOYSA-N 2-phenylmethoxypropane-1,3-diol Chemical compound OCC(CO)OCC1=CC=CC=C1 UDIPIOHLDFSMLR-UHFFFAOYSA-N 0.000 claims description 4
- 239000002841 Lewis acid Substances 0.000 claims description 4
- 125000001231 benzoyloxy group Chemical group C(C1=CC=CC=C1)(=O)O* 0.000 claims description 4
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 4
- 229940125833 compound 23 Drugs 0.000 claims description 4
- PSCMQHVBLHHWTO-UHFFFAOYSA-K indium(iii) chloride Chemical compound Cl[In](Cl)Cl PSCMQHVBLHHWTO-UHFFFAOYSA-K 0.000 claims description 4
- 150000007517 lewis acids Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 4
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 claims description 3
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 3
- 229910015900 BF3 Inorganic materials 0.000 claims description 2
- 229910021617 Indium monochloride Inorganic materials 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 229940125904 compound 1 Drugs 0.000 claims description 2
- 238000006482 condensation reaction Methods 0.000 claims description 2
- APHGZSBLRQFRCA-UHFFFAOYSA-M indium(1+);chloride Chemical compound [In]Cl APHGZSBLRQFRCA-UHFFFAOYSA-M 0.000 claims description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 2
- 239000011592 zinc chloride Substances 0.000 claims description 2
- 235000005074 zinc chloride Nutrition 0.000 claims description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 16
- 239000000243 solution Substances 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000000047 product Substances 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- 239000012071 phase Substances 0.000 description 28
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 230000001276 controlling effect Effects 0.000 description 21
- 238000005303 weighing Methods 0.000 description 20
- 150000003904 phospholipids Chemical class 0.000 description 17
- 239000002502 liposome Substances 0.000 description 14
- 238000003756 stirring Methods 0.000 description 14
- 239000012085 test solution Substances 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 239000012295 chemical reaction liquid Substances 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 239000012535 impurity Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000012362 glacial acetic acid Substances 0.000 description 8
- 239000005457 ice water Substances 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000000889 atomisation Methods 0.000 description 7
- 238000007865 diluting Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 238000010606 normalization Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 5
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 5
- 229940042880 natural phospholipid Drugs 0.000 description 5
- 238000007086 side reaction Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 229960003942 amphotericin b Drugs 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 3
- 238000006130 Horner-Wadsworth-Emmons olefination reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 3
- 229960001097 amifostine Drugs 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 2
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 description 2
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UHUSDOQQWJGJQS-QNGWXLTQSA-N 1,2-dioctadecanoyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-QNGWXLTQSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- RNVYQYLELCKWAN-RXMQYKEDSA-N [(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@@H](CO)O1 RNVYQYLELCKWAN-RXMQYKEDSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013064 chemical raw material Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- JEIJBKDXJPNHGD-UHFFFAOYSA-N chloroform;pyridine Chemical compound ClC(Cl)Cl.C1=CC=NC=C1 JEIJBKDXJPNHGD-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
- C07F9/6574—Esters of oxyacids of phosphorus
- C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
Abstract
The invention relates to a preparation process of distearoyl phosphatidyl glycerol sodium (DSPGNa). The glycerol end is firstly connected to a phosphorus-oxygen bond and then connected with the intermediate 7, so that the utilization rate of the expensive intermediate 7 is improved as much as possible.
Description
Technical Field
The invention relates to the field of synthesis, and in particular relates to a preparation process of distearoyl phosphatidyl glycerol sodium.
Background
Bangham teaches that liposomes (liposomes) were first discovered in 1965, and the liposome technology is also referred to as "biolistic" technology or fourth generation targeted drug delivery technology. With the popularization of liposome technology, liposome as a novel drug carrier has the advantages of low toxicity, long in-vivo circulation time, targeting property, slow release and the like, and is increasingly paid more attention to the aspect of drug directional delivery.
Composition of the liposomes: lipid (phospholipid) and additive.
1. Phospholipids: including natural phospholipids and synthetic phospholipids. The structure of phospholipids is characterized by a hydrophilic group consisting of one phosphate group and one quaternary ammonium salt group, and a lipophilic group consisting of two longer hydrocarbon groups. The natural phospholipid is mainly lecithin (phosphatidylcholine, PC), is derived from egg yolk and soybean, and is neutral. The synthetic phospholipid mainly comprises DPPC (dipalmitoylphosphatidylcholine), DPPE (dipalmitoylphosphatidylethanolamine), DSPC (distearoylphosphatidylcholine), DSPG (distearoylphosphatidylglycerol) and the like, which all belong to hydrogenated phospholipids, have the characteristics of stable property, strong oxidation resistance, stable finished product and the like, and are preferred auxiliary materials abroad.
2. Cholesterol: cholesterol and phospholipids are the basic substances that together constitute cell membranes and liposomes. Cholesterol has the effect of regulating membrane fluidity and may be referred to as a liposomal "fluidity buffer".
Natural phospholipids are the major components of biological membranes and are present in almost all cells of the organism. Phospholipids can be classified into glycerophospholipids and sphingophospholipids according to their chemical structure. The glycerophospholipid consists of three parts, namely a glycerol skeleton, fatty acid and a hydrophilic head group containing hydroxyl. Sphingomyelin differs from glycerophospholipids only in the substitution of glycerol with sphingosine. The natural phospholipid is generally separated and extracted from soybean or egg yolk, and phospholipid compounds are obtained by processing, enzyme modification or semi-synthesis, but the phospholipid obtained by the method is a mixture of various phospholipids or homologues of the phospholipids, is not single or high-purity phospholipid, and has certain application limitation.
Distearoyl phosphatidyl glycerol sodium (DSPGNa) is one of important auxiliary materials for preparing liposome, is different from natural phospholipid DSPGNa, belongs to synthetic phospholipid, and has determined chemical components. Due to the unique structure and physicochemical properties, the amifostine liposome plays an extremely important role in the development of some key preparations, wherein the most representative is the liposome drug amifostine (amphotericin B liposome for injection), and the amifostine liposome is suitable for patients infected by deep fungi such as candida, aspergillus, cryptococcus and the like. Amphotericin B is a drug for deep fungal infections, but it is highly toxic to the kidneys. Amphotericin liposome B solves this problem to a large extent, and can be used for patients who cannot use an effective dose of amphotericin B due to renal injury or drug toxicity, or who have been ineffectively treated with amphotericin B. The phospholipid material used by the liposome drug ampirome comprises: DSPG (distearoyl phosphatidyl glycerol), HSPC (hydrogenated soy lecithin), CHO (high purity cholesterol). In view of the more and more extensive application of DSPGNa in liposome research and large market demand, the development of the method for synthesizing distearoyl phosphatidyl glycerol sodium DSPGNa which is suitable for industrial production prospect has important significance.
The preparation of DSPGNa was first mentioned in the Journal of Biological Chemistry (1958),232,895-901 (By Baer, Erich; Buchnea, Ddyro). With phosphorus oxychloride (POCl)3) D-alpha, beta-diol and D-acetonylglycerol are used as main raw materials, equimolar D-alpha, beta-diol and pyridine are kept at 0 ℃ in ice bath, and are dripped into equimolar phosphorus oxychloride solution, and after dripping, the temperature is raised to room temperature, and stirring is carried out for 1.0 hr. Cooling to 10 deg.C, adding dropwise equimolar D-acetone glycerol and pyridine, heating to room temperature after dropwise addition, stirring for 2.5hr, adding dropwise equimolar water, treating with 2N glacial sulfuric acid solution, saturated sodium carbonate solution and water, and concentrating under reduced pressure to obtain crude product. Dispersing the crude product in acetone solution, treating at-85 deg.C for 2.0hr, and centrifuging to obtain dioleoyl-L-alpha-glycerophosphoryl-L-glycerol.
Adding the dioleoyl-L-alpha-glyceryl phosphoryl-L-glycerol into platinum oxide as a catalyst and ethanol as a solvent, hydrogenating at normal pressure to obtain a crude product, and refining with acetone to obtain the distearoyl-L-alpha-glyceryl phosphoryl-L-glycerol.
This route seems to be simple, but we are trying to directly react the intermediate 7[ (2S) -3-hydroxy-1, 2-propanediyl distearate by a process similar to the one described above]When the intermediate 4 (acetonide condensed glycerol) is coupled in a stepwise manner, the reaction activity of phosphorus oxychloride is high, the selectivity of the reaction with hydroxyl is poor, even if the molar ratio is controlled to be 1:1, phosphorus oxychloride can be coupled with a plurality of alcohols at the same time, so that the product is a mixture of a plurality of phospholipids, and the purity of the crude intermediate 9 is only 40-50%, and the crude intermediate is mixed with a plurality of phospholipid components through mass spectrometric detection and analysis. Among them, the largest impurity (55-65% in total), MS (EI +): m/e-933.5, consistent with the structure of compound 10 below, should be a monostearyldiglycerol impurity; there is also one major impurity (20-30% of total impurities), MS (EI +): m/e-1493.7, corresponding to the structure of compound 11 below, should be a distearoyl monoglycerol impurity;there is one non-major impurity (5-10% of total impurities), MS (EI +): m/e-1311.83, consistent with the structure of compound 12 below, should be a distearoyl impurity. The intermediate 5 is difficult to purify, and can only be subjected to the next reaction after being separated and purified by column chromatography at present. Aiming at the side reaction caused by overhigh activity of phosphorus oxychloride, measures of reducing the reaction temperature, controlling the dropping speed, increasing the reaction system and the like are adopted successively, and the reaction is hopefully controlled at a phosphodiester stage, but the failure is ended. Thus passing through the POCl3The stepwise substitution of chlorine in the molecule to synthesize diesters of phosphoric acid, although straightforward, is not an effective method.
In addition, we have found that side reactions also occur when the propylidene protecting group is deprotected under acidic conditions, and we refer to the hydrolysis conditions in S.Pedatella et al/Carbohydrate Research 343(2008) 31-38: hydrolysis reaction was carried out with 90% TFA at room temperature for 3.0hr, and it was found that 15-20% of the product was produced by cleavage of one side of the stearic acid chain in the molecular structure, and Lysophospholipid (LSPG) as a by-product 13 was produced, while stearic acid as a by-product 14 was detected. We tried to perform the depropylidene reaction with slightly weaker glacial acetic acid, but heating to above 80 ℃ was required to allow the reaction to proceed, and side reactions were still unavoidable.
The synthetic route is as follows:
the impurity structure contained in intermediate 9 is as follows:
the structure of the acid degradation impurity of the product 1 is as follows:
2015, Shigeki Sano et alUsing Still-Gennari reagent [ O, O' bis (2,2, 2-trifluoroethyl) phosphoacetic acid methyl ester]Ester-type glycerophosphatidic acid (PA), Phosphatidylethanolamine (PE) and Phosphatidylcholine (PC) are efficiently constructed through Horner-Wadsworth-Emmons (HWE) reaction. The HWE reaction is an improvement over the Wittig reaction, which uses a stable phosphonate carbanion, instead of a phosphoylide, to react with aldehydes and ketones to form olefins, the products being predominantly E-type olefins, and the dihydrocarbyl phosphates produced in this reaction are usually disposed of as by-products, but are the major target products in the synthesis of phospholipids. According to this document, we attempted to synthesize DSPGNa using Still-Gennari reagent, and we found the trifluoroacetyl group (CF) in Still-Gennari reagent3CH2O-) is a relatively suitable leaving group, has better reaction selectivity with alcohol, can realize gradual coupling with different alcohols, has simple operation, can obtain an intermediate 17 with the purity of 85-90 percent, can be directly used for the next reaction, but still avoids acidic degradation impurities when the propylidene group is removed. The trifluoroethanol group used in the Still-Gennari reagent broadens new ideas for the preparation of phosphodiesters.
The synthetic route is as follows:
disclosure of Invention
The invention aims to provide a preparation process of distearoyl phosphatidyl glycerol sodium (DSPGNa) with simple synthetic route, low production cost, high yield and high purity aiming at the technical problems.
The technical scheme of the invention is as follows:
a preparation process of distearoyl phosphatidyl glycerol sodium (DSPGNa) comprises the following reaction equation:
the reaction equation for the preparation of intermediate 19(R ═ TFE) [5- (benzyloxy) -2- (2,2, 2-trifluoroethoxy) -2-oxo-1, 3, 2-dioxaphosphorinane ]:
the method comprises the following specific steps:
1. preparation of intermediate 19(R ═ TFE): phosphorus oxychloride of the intermediate 22 and a compound 23 (2-benzyloxy-1, 3-propylene glycol) are subjected to a disubstituted reaction in the presence of an organic alkali reagent, and are subjected to a monosubstitution reaction with trifluoroethanol in the presence of the organic alkali reagent to obtain an intermediate 19, and the intermediate 19 is subjected to reduced pressure distillation to obtain a pure product, wherein the organic alkali can be DBU (1, 8-diazabicycloundecene-7-ene), DIEA (N, N-diisopropylethylamine), TEA (triethylamine) and the like; preparation of intermediate 19(R ═ p-NP): carrying out disubstituted reaction on the intermediate 22 phosphorus oxychloride and the compound 23 (2-benzyloxy-1, 3-propylene glycol) in the presence of an organic base reagent, carrying out monosubstitution on the phosphorus oxychloride and 4-nitro-phenol (p-NP) in the presence of the organic base reagent to obtain an intermediate 19, and carrying out reduced pressure distillation to obtain a pure product, wherein the organic base can be DBU (1, 8-diazabicycloundecen-7-ene), DIEA (N, N-diisopropylethylamine), TEA (triethylamine) and the like;
2. preparation of intermediate 20: intermediate 7[ (2S) -3-hydroxy-1, 2-propanediyl distearate ] with intermediate 19[5- (benzyloxy) -2- (2,2, 2-trifluoroethoxy) -2-oxo-1, 3, 2-dioxaphosphorinane ], a molar ratio of 1:1 feeding, and carrying out condensation reaction in the presence of an organic base reagent to obtain an intermediate 20(R) -3- { [5- (benzoyloxy) -2-oxo-1, 3, 2-dioxaphosphin-2-yl ] oxy } propane-1, 2-diethyl distearate, wherein the organic base reagent can be DBU, DIEA, TEA and the like;
3. preparation of intermediate 21: intermediate 20 is analogous to boron trifluoride, indium trichloride (InCl)3) Tin tetrachloride (SnCl)4) Zinc chloride (ZnCl)2) Ring opening is carried out under the catalysis of Lewis acid to obtain an intermediate 21(2R) -3- { [2- (benzoyloxy) -3-hydroxypropoxy]-hydroxy-phosphoryloxy } propane-1, 2-diethyldistearate;
4. preparation of compound 1: and removing benzyl (Bzl) from the intermediate 21 under the action of trimethyl iodosilane (TMSI), and sodium methoxide to form sodium salt to obtain the target compound 1.
The invention has the beneficial effects that: according to the structure of the compound, the compound is split into butt joint of two fragments by taking a middle phosphorus-oxygen bond as a center. The glycerol end is firstly connected to a phosphorus-oxygen bond and then connected with the intermediate 7, so that the utilization rate of the expensive intermediate 7 is improved as much as possible.
In addition, the glycerol terminal is connected in a disubstituted mode, so that only one active leaving terminal is exposed in the whole intermediate 19, and the connection of the intermediate 7 is purer. The ring opening of the intermediate 20 is catalyzed by a lewis acid, a possible mechanism of which is: boron trifluoride diethyl etherate is used as a Lewis acid center, so that charges on O deviate, the polarity of a P-O bond is increased, and in this case, a nucleophilic reagent attacks a phosphorus-oxygen bond with small steric hindrance to generate a substitution reaction to generate a compound 21. The ring-opening condition is mild, and the stearoyl phosphoryl bond on the other side is hardly influenced. Finally, the benzyl protecting group can be removed by hydrogenation or by using iodotrimethylsilane, which we prefer from a safety point of view.
The lewis acid catalyzed ring opening mechanism is as follows (taking boron trifluoride diethyl ether as an example):
phosphorus oxychloride is a common chemical raw material, and is cheap and easy to obtain. We engineered it into the structural form of intermediate 19 by means of group modification. The disubstituted structure in the intermediate 19 brings many convenient conditions for the following reaction, so that side reactions caused by too high activity are avoided; in addition, in the whole reaction process, no acid and alkali are involved, the reaction is mild, side reactions are few, and the obtained crude product is simply refined to reach the pharmaceutical adjuvant standard; the preparation process of the product is also relatively simple, all conventional, and only in the preparation of intermediate 19, the final product needs to be purified by reduced pressure distillation.
Detailed Description
Example 1: preparation of sodium distearoyl phosphatidyl glycerol (DSPGNa)
1.1 preparation of intermediate 20
Materials:
the operation is as follows: weighing 710.00 g of intermediate 16.00mmol, 195.22 g of intermediate 16mmol and 100ml of toluene, uniformly mixing, cooling in an ice water bath, controlling the temperature of a reaction solution to be 0-10 ℃, slowly dripping a solution prepared from 4.87g of DBU and 10ml of toluene into the reaction solution, controlling the dripping time to be 10-15min, heating the temperature of the reaction solution to be 20-30 ℃ and stirring for reaction for 2.0-3.0hr, filtering to remove precipitates after the reaction is finished, obtaining an organic phase, fully washing the organic phase with 1% hydrochloric acid solution and saturated sodium chloride solution, drying the obtained organic phase with anhydrous sodium sulfate, and concentrating under reduced pressure to obtain 12.83g of white solid, namely the product intermediate 20, wherein the yield is as follows: 94.21 percent. And (3) product purity: 95.42 percent
HPLC conditions:
octadecylsilane chemically bonded silica is used as filler (4.6mm × 250mm, 5 μm) or chromatographic column with equivalent performance; gradient elution was performed according to the following table using water-glacial acetic acid (100:0.1) as mobile phase a and methanol as mobile phase B; the flow rate was 1.0ml per minute; the detector is a CAD detector, and the atomization temperature is 35 ℃; the column temperature was 30 ℃ and the amount of sample was 10. mu.l.
The gradiometer is as follows:
time (min) | Mobile phase A (%) | Mobile phase B (%) |
0 | 50 | 50 |
10 | 50 | 50 |
40 | 15 | 85 |
45 | 15 | 85 |
46 | 50 | 50 |
55 | 50 | 50 |
Test solution: weighing about 10mg of the product, accurately weighing, placing in a 20ml measuring flask, adding methanol for dissolving, diluting to scale, and shaking uniformly to obtain a test solution.
The determination method comprises the following steps: the percentage of the main peak area should not be less than 95% as calculated by area normalization.
1.2 preparation of intermediate 21
The operation is as follows:
weighing 2010.00 g of intermediate 11.76mmol, adding 100ml of toluene, mixing uniformly, cooling in ice water bath, controlling the temperature of reaction liquid at 0-10 ℃, slowly dripping a solution prepared from 0.18g of boron trifluoride diethyl etherate solution (47%) and 10ml of toluene into the reaction liquid, controlling the dripping time to be 5-10min, heating the temperature of the reaction liquid to 20-30 ℃, stirring and reacting for 7.0-8.0hr, and after the reaction is finished, using 1% NaHCO for an organic phase3The solution and a saturated sodium chloride solution were sufficiently washed, and the obtained organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure to dryness to obtain 9.21g of a white solid as a product intermediate 21 in yield: 90.19 percent. And (3) product purity: 91.08 percent
HPLC conditions:
octadecylsilane chemically bonded silica is used as filler (4.6mm × 250mm, 5 μm) or chromatographic column with equivalent performance; gradient elution was performed according to the following table using water-glacial acetic acid (100:0.1) as mobile phase a and methanol as mobile phase B; the flow rate was 1.0ml per minute; the detector is a CAD detector, and the atomization temperature is 35 ℃; the column temperature was 30 ℃ and the amount of sample was 10. mu.l.
The gradiometer is as follows:
time (min) | Mobile phase A (%) | Mobile phase B (%) |
0 | 50 | 50 |
10 | 50 | 50 |
40 | 15 | 85 |
45 | 5 | 95 |
46 | 50 | 50 |
55 | 50 | 50 |
Test solution: weighing about 10mg of the product, accurately weighing, placing in a 20ml measuring flask, adding methanol for dissolving, diluting to scale, and shaking uniformly to obtain a test solution.
The determination method comprises the following steps: the percentage of the main peak area should not be less than 90% as calculated by area normalization.
1.3 preparation of product 1
Materials:
the operation is as follows:
weighing 2110.00 g of intermediate 11.50mmol, adding 100ml of toluene, uniformly mixing, cooling in a ice salt bath, controlling the temperature of a reaction solution to be-10-0 ℃, slowly dripping a solution prepared from 4.60g of iodotrimethylsilane solution and 10ml of toluene into the reaction solution, controlling dripping to be finished within 10-20min, heating the temperature of the reaction solution to be 10-20 ℃, stirring for reaction for 0.5-1.0hr, after the reaction is finished, adding 5ml of methanol solution containing 0.62g of sodium methoxide, separating out white solid, filtering, drying to obtain 8.16g of white solid, wherein the yield is 1: 88.54 percent. And (3) product purity: 97.76 percent
HPLC conditions:
using C8(4.6 mm. times.250 mm, 5 μm) or equivalent performance columns; taking 10mmol/L ammonium acetate buffer solution (adjusting pH to 4.0 with glacial acetic acid) as mobile phase A, taking methanol as mobile phase B, and performing gradient elution according to the following table; the flow rate was 1.0ml per minute; the detector is a CAD detector, and the atomization temperature is 35 ℃; the column temperature was 30 ℃ and the amount of sample was 10. mu.l.
The gradiometer is as follows:
time (min) | Mobile phase A (%) | Mobile phase B (%) |
0 | 40 | 60 |
10 | 40 | 60 |
40 | 10 | 90 |
45 | 10 | 90 |
46 | 40 | 60 |
55 | 40 | 60 |
Test solution: weighing about 10mg of the product, accurately weighing, placing in a 20ml measuring flask, adding methanol for dissolving, diluting to scale, and shaking uniformly to obtain a test solution.
The determination method comprises the following steps: the percentage of the main peak area should not be less than 95% as calculated by area normalization.
19(R ═ TFE) [5- (benzyloxy) -2- (2,2, 2-trifluoroethoxy) -2-oxo-1, 3, 2-dioxaphosphorinane ] prepared by the method of example 3.
Example 2: preparation of sodium distearoyl phosphatidyl glycerol (DSPGNa)
2.1 preparation of intermediate 20
Materials:
the operation is as follows:
weighing 710.00 g of intermediate 16.00mmol, 195.84 g of intermediate 16mmol and 100ml of dichloromethane, uniformly mixing, cooling in ice water bath, controlling the temperature of reaction liquid at 0-10 ℃, slowly dripping a solution prepared from 3.24g of triethylamine and 10ml of dichloromethane into the reaction liquid, controlling the dripping time to be 10-15min, heating the temperature of the reaction liquid to 20-30 ℃ and stirring for reaction for 2.0-3.0hr, after the reaction is finished, filtering to remove precipitates to obtain an organic phase, fully washing the organic phase with 1% hydrochloric acid solution and saturated sodium chloride solution, drying the obtained organic phase with anhydrous sodium sulfate, concentrating under reduced pressure to obtain 12.83g of white solid, namely the product intermediate 20, wherein the yield is as follows: 94.21 percent. And (3) product purity: 96.32 percent
HPLC conditions:
octadecylsilane chemically bonded silica is used as filler (4.6mm × 250mm, 5 μm) or chromatographic column with equivalent performance; gradient elution was performed according to the following table using water-glacial acetic acid (100:0.1) as mobile phase a and methanol as mobile phase B; the flow rate was 1.0ml per minute; the detector is a CAD detector, and the atomization temperature is 35 ℃; the column temperature was 30 ℃ and the amount of sample was 10. mu.l.
The gradiometer is as follows:
time (min) | Mobile phase A (%) | Mobile phase B (%) |
0 | 40 | 60 |
10 | 40 | 60 |
45 | 5 | 95 |
50 | 5 | 95 |
51 | 40 | 60 |
60 | 40 | 60 |
Test solution: weighing about 10mg of the product, accurately weighing, placing in a 20ml measuring flask, adding methanol for dissolving, diluting to scale, and shaking uniformly to obtain a test solution.
The determination method comprises the following steps: the percentage of the main peak area should not be less than 95% as calculated by area normalization.
2.2 preparation of intermediate 21
Materials:
the operation is as follows:
weighing 2010.00 g of intermediate 11.75mmol, adding 100ml of Tetrahydrofuran (THF), mixing uniformly, cooling in ice water bath, controlling the temperature of the reaction solution at 0-10 ℃, slowly dripping a solution prepared from 0.33g of stannic chloride and 10ml of THF into the reaction solution, controlling the dripping time to be 5-10min, heating the temperature of the reaction solution to 20-30 ℃, stirring for reaction for 7.0-8.0hr, and after the reaction is finished, using 1% NaHCO for an organic phase3The solution and a saturated sodium chloride solution were sufficiently washed, and the obtained organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure to dryness to obtain 9.08g of a white solid as a product intermediate 21 in yield: 88.92 percent.
And (3) product purity: 92.07 percent of
HPLC conditions:
octadecylsilane chemically bonded silica is used as filler (4.6mm × 250mm, 5 μm) or chromatographic column with equivalent performance; gradient elution was performed according to the following table using water-glacial acetic acid (100:0.1) as mobile phase a and methanol as mobile phase B; the flow rate was 1.0ml per minute; the detector is a CAD detector, and the atomization temperature is 35 ℃; the column temperature was 30 ℃ and the amount of sample was 10. mu.l.
The gradiometer is as follows:
time (min) | Mobile phase A (%) | Mobile phase B (%) |
0 | 30 | 70 |
10 | 30 | 70 |
45 | 10 | 90 |
50 | 10 | 90 |
51 | 30 | 70 |
60 | 30 | 70 |
Test solution: weighing about 10mg of the product, accurately weighing, placing in a 20ml measuring flask, adding methanol for dissolving, diluting to scale, and shaking uniformly to obtain a test solution.
The determination method comprises the following steps: the percentage of the main peak area should not be less than 90% as calculated by area normalization.
2.3 preparation of product 1
Materials:
the operation is as follows:
weighing 2110.00 g of intermediate 11.50mmol, adding 100ml of toluene, uniformly mixing, cooling in a ice salt bath, controlling the temperature of a reaction solution to be-10-0 ℃, slowly dripping a solution prepared from 4.60g of iodotrimethylsilane solution and 10ml of toluene into the reaction solution, controlling dripping to be finished within 10-20min, heating the temperature of the reaction solution to be 10-20 ℃, stirring for reaction for 0.5-1.0hr, after the reaction is finished, adding 5ml of methanol solution containing 0.62g of sodium methoxide, separating out white solid, filtering, drying to obtain 7.95g of white solid, wherein the yield is 1: 86.26 percent. And (3) product purity: 98.13 percent
HPLC conditions: same as example 1 (1.3)
19(R ═ p-NP) [5- (benzyloxy) -2- (4-nitro-phenoxy) -2-oxo-1, 3, 2-dioxaphosphorinane ] was prepared as in example 4.
Example 3: preparation of 19(R ═ TFE) [5- (benzyloxy) -2- (2,2, 2-trifluoroethoxy) -2-oxo-1, 3, 2-dioxaphosphorinane ]
The operation is as follows:
weighing 2311.88 g of intermediate 65.22mmol, DBU29.98g of 195.66mmol and 200ml of dichloromethane, uniformly mixing, cooling in ice-water bath, controlling the temperature of the reaction solution to be 0-5 ℃, slowly dripping a solution prepared from 2210.00 g of phosphorus oxychloride intermediate 65.22mmol and 20ml of dichloromethane into the reaction solution, controlling the dripping time to be 20-30min, heating the temperature of the reaction solution to be 20-30 ℃, stirring and reacting for 0.5-1.0hr, cooling in ice-water bath after the reaction is finished, controlling the temperature of the reaction solution to be 0-5 ℃, slowly dripping a solution prepared from 6.52g of trifluoroethanol 65.22mmol and 10ml of dichloromethane into the reaction solution, controlling the dripping time to be 10-20min, heating the reaction solution to be 20-30 ℃, stirring and reacting for 0.5-1.0hr, filtering to remove precipitates to obtain a dichloromethane solution, distilling under reduced pressure to remove an organic phase, distilling at 140 ℃/5mmHg, the fractions were collected to give 15.5g of a colorless oily liquid as product intermediate 19, yield: 72.86 percent. And (3) product purity: 98.74 percent
HPLC conditions:
octadecylsilane chemically bonded silica is used as filler (4.6mm × 250mm, 5 μm) or chromatographic column with equivalent performance; gradient elution was performed according to the following table using water-glacial acetic acid (100:0.1) as mobile phase a and methanol as mobile phase B; the flow rate was 1.0ml per minute; the detector is a CAD detector, and the atomization temperature is 35 ℃; the column temperature was 30 ℃ and the amount of sample was 10. mu.l.
The gradiometer is as follows:
time (min) | Mobile phase A (%) | Mobile phase B (%) |
0 | 95 | 5 |
10 | 95 | 5 |
45 | 80 | 20 |
50 | 80 | 20 |
51 | 95 | 5 |
60 | 95 | 5 |
Test solution: taking about 40mg of the product, accurately weighing, placing in a 20ml measuring flask, adding methanol for dissolving, diluting to scale, and shaking up to obtain a test solution.
The determination method comprises the following steps: the percentage of the main peak area should not be less than 95% as calculated by area normalization.
Example 4: preparation of 19(R ═ p-NP) [5- (benzyloxy) -2- (4-nitro-phenoxy) -2-oxo-1, 3, 2-dioxaphosphorinane ]
Materials:
the operation is as follows:
weighing 2311.88 g of intermediate 65.22mmol, DBU29.98g of 195.66mmol and 200ml of dichloromethane, uniformly mixing, cooling in ice-water bath, controlling the temperature of reaction liquid to be 0-5 ℃, slowly dripping solution prepared by 2210.00 g of phosphorus oxychloride intermediate 65.22mmol and 20ml of dichloromethane into the reaction liquid, controlling the dripping time to be 20-30min, heating the temperature of the reaction liquid to be 20-30 ℃, stirring and reacting for 0.5-1.0hr, cooling in ice-water bath after the reaction is finished, controlling the temperature of the reaction liquid to be 0-5 ℃, slowly dripping solution prepared by 9.07g of 65.22mmol of 4-nitro-phenol and 10ml of dichloromethane into the reaction liquid, controlling the dripping time to be 10-20min, heating the temperature of the reaction liquid to be 20-30 ℃, stirring and reacting for 0.5-1.0hr, filtering to remove precipitate, obtaining dichloromethane solution, distilling under reduced pressure to remove an organic phase, 155 ℃ and 160 ℃/5mmHg, collecting the fraction to obtain 17.8g of colorless oily liquid as the product intermediate 19, with the yield: 74.72 percent. And (3) product purity: 99.04% HPLC conditions:
octadecylsilane chemically bonded silica is used as filler (4.6mm × 250mm, 5 μm) or chromatographic column with equivalent performance; gradient elution was performed according to the following table using water-glacial acetic acid (100:0.1) as mobile phase a and methanol as mobile phase B; the flow rate was 1.0ml per minute; the detector is a CAD detector, and the atomization temperature is 35 ℃; the column temperature was 30 ℃ and the amount of sample was 10. mu.l.
The gradiometer is as follows:
time (min) | Mobile phase A (%) | Mobile phase B (%) |
0 | 90 | 10 |
10 | 90 | 10 |
35 | 30 | 70 |
40 | 30 | 70 |
41 | 90 | 10 |
50 | 90 | 10 |
Test solution: taking about 20mg of the product, accurately weighing, placing in a 20ml measuring flask, adding methanol for dissolving, diluting to scale, and shaking up to obtain a test solution.
The determination method comprises the following steps: the percentage of the main peak area should not be less than 97% as calculated by area normalization.
Comparative example 1:
according to the DSPG synthetic method in CN103864840A, the concrete steps are as follows:
cooling (R) -1, 2-Glycerol distearate-Glycerol-3-phosphatidic acid 5.0g (7.09mmol) and 500ml of a chloroform-pyridine mixed solution (chloroform: pyridine ═ 2:1) to 0-5 ℃, and adding dropwise 2, 2-dimethyl-4-methanol0.94g (7.11mmol) of-1, 3-dioxolane was stirred at the same temperature for 5.0hr, and the temperature was raised to 30 ℃ and stirring was continued for 20 hr. The reaction was stopped, the pH was adjusted to 2 with 1N hydrochloric acid solution, washed 3 times with 150ml of saturated sodium chloride solution, and the organic layer was concentrated to dryness under reduced pressure. Adding 20ml of 20% HAc solution into the concentrate, stirring at 60 deg.C for 2.0hr, and adding saturated NaHCO3The solution was adjusted to pH 7, extracted with chloroform 250ml x 3, washed 3 times with 100ml saturated sodium chloride solution and the organic layer concentrated to dryness under reduced pressure to give the crude product. And (3) carrying out column chromatography purification on 4.5g of the crude product by using 450g of silica gel (100 meshes and 200 meshes), developing agent chloroform, methanol and water at a ratio of 30:6:1 to obtain a product DSPG2.76g, wherein the yield is as follows: 49.95%, product purity: 97.82 percent
HPLC conditions: same as example 1 (1.3)
Comparing the results of the comparative example 1 and the experimental examples, the product yield in the examples is higher, and complicated column chromatography purification is avoided, so that the production is more convenient.
Claims (6)
2. the process for preparing sodium distearoylphosphatidylglycerol (dspgsna) according to claim 1, wherein the reaction equation for preparing intermediate 19(R ═ TFE) [5- (benzyloxy) -2- (2,2, 2-trifluoroethoxy) -2-oxo-1, 3, 2-dioxaphosphorinane ]:
the method comprises the following specific steps:
preparation of intermediate 19(R ═ TFE): carrying out disubstituted reaction on the intermediate 22 phosphorus oxychloride and the compound 23 (2-benzyloxy-1, 3-propylene glycol) in the presence of an organic base reagent, carrying out monosubstitution on the phosphorus oxychloride and trifluoroethanol in the presence of the organic base reagent to obtain an intermediate 19(R ═ TFE)5- (benzyloxy) -2- (2,2, 2-trifluoroethoxy) -2-oxo-1, 3, 2-dioxaphosphorinane ], and carrying out reduced pressure distillation to obtain a pure product; preparation of intermediate 19(R ═ p-NP): the intermediate 22 phosphorus oxychloride and the compound 23 (2-benzyloxy-1, 3-propylene glycol) are subjected to disubstituted reaction in the presence of an organic alkali reagent, and are subjected to monosubstitution reaction with 4-nitro-phenol (p-NP) in the presence of an organic alkali reagent to obtain an intermediate 19(R ═ p-NP)5- (benzyloxy) -2- (4-nitro-phenoxy) -2-oxo-1, 3, 2-dioxaphosphorinane, and the intermediate is subjected to reduced pressure distillation to obtain a pure product.
3. Process for the preparation of sodium distearoylphosphatidylglycerol (DSPGNa) according to claim 1, wherein the intermediate 20(R) -3- { [5- (benzoyloxy) -2-oxo-1, 3, 2-dioxaphosphin-2-yl ] oxy } propane-1, 2-diethyldistearate is prepared: intermediate 7[ (2S) -3-hydroxy-1, 2-propanediyl distearate ] with intermediate 195- (benzyloxy) -2- (2,2, 2-trifluoroethoxy) -2-oxo-1, 3, 2-dioxaphosphorinane or 5- (benzyloxy) -2- (4-nitro-phenoxy) -2-oxo-1, 3, 2-dioxaphosphorinane in a molar ratio of 1:1, and carrying out condensation reaction in the presence of an organic base reagent to obtain an intermediate 20.
4. The process for the preparation of sodium distearoylphosphatidylglycerol (dspgcna) according to claim 1, wherein the intermediate 21: intermediate 20 is analogous to boron trifluoride, indium trichloride (InCl)3) Tin tetrachloride (SnCl)4) Zinc chloride (ZnCl)2) Ring opening under the catalysis of Lewis acid to obtain an intermediate 21.
5. The process for the preparation of distearoylphosphatidylglycerol sodium (dspgcna) according to claim 1, wherein compound 1: and removing benzyl (Bzl) from the intermediate 21(2R) -3- { [2- (benzoyloxy) -3-hydroxypropoxy ] -hydroxy-phosphoryloxy } propane-1, 2-diethyl distearate under the action of trimethyl iodosilane (TMSI), and obtaining sodium methoxide to obtain the target compound 1.
6. The process for preparing distearoyl phosphatidyl glycerol sodium (DSPGNa) according to claim 2 or 3, wherein the organic base is one or more of DBU (1, 8-diazabicycloundecen-7-ene), DIEA (N, N-diisopropylethylamine) and TEA (triethylamine).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110754813.XA CN113354679A (en) | 2021-07-05 | 2021-07-05 | Preparation process of distearoyl phosphatidyl glycerol sodium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110754813.XA CN113354679A (en) | 2021-07-05 | 2021-07-05 | Preparation process of distearoyl phosphatidyl glycerol sodium |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113354679A true CN113354679A (en) | 2021-09-07 |
Family
ID=77538197
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110754813.XA Pending CN113354679A (en) | 2021-07-05 | 2021-07-05 | Preparation process of distearoyl phosphatidyl glycerol sodium |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113354679A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118307586A (en) * | 2024-06-11 | 2024-07-09 | 天津凯莱英制药有限公司 | Synthetic phospholipid DSPG, preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003679A1 (en) * | 1995-07-17 | 1997-02-06 | Cephalon, Inc. | Phosphorous-containing cysteine and serine protease inhibitors |
CN103864840A (en) * | 2014-03-11 | 2014-06-18 | 苏州东南药业股份有限公司 | Preparation method of artificial phospholipid DSPG |
CN105985373A (en) * | 2015-04-10 | 2016-10-05 | 江苏东南纳米材料有限公司 | New method for preparing (R)-1,2-di-fatty acid glycerol phosphatidyl glyceride |
-
2021
- 2021-07-05 CN CN202110754813.XA patent/CN113354679A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997003679A1 (en) * | 1995-07-17 | 1997-02-06 | Cephalon, Inc. | Phosphorous-containing cysteine and serine protease inhibitors |
CN103864840A (en) * | 2014-03-11 | 2014-06-18 | 苏州东南药业股份有限公司 | Preparation method of artificial phospholipid DSPG |
CN105985373A (en) * | 2015-04-10 | 2016-10-05 | 江苏东南纳米材料有限公司 | New method for preparing (R)-1,2-di-fatty acid glycerol phosphatidyl glyceride |
Non-Patent Citations (2)
Title |
---|
ERICH BAER 等: "Synhesis of Saturated and Unsaturated Phosphatidyl Glycerols", 《JOURNAL OF BIOLOGICAL CHEMISTRY》, vol. 232, pages 895 - 901 * |
SHIGEKI SANO 等: "A novel synthetic approach to glycerophospholipids via Horner–Wadsworth–Emmons reaction of mixed phosphonoacetate", 《TETRAHEDRON LETTERS》, vol. 56, pages 4686 - 4688 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118307586A (en) * | 2024-06-11 | 2024-07-09 | 天津凯莱英制药有限公司 | Synthetic phospholipid DSPG, preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kates et al. | pH-dissociation characteristics of cardiolipin and its 2′-deoxy analogue | |
EP2125838B1 (en) | Improved process for the preparation of oxidized phospholipids | |
EP0116566B1 (en) | New d-mannite derivatives as starting products for the synthesis of phospholipids | |
Brockerhoff et al. | Improved synthesis of choline phospholipids | |
US9968622B2 (en) | High-purity phospholipids | |
CN113354679A (en) | Preparation process of distearoyl phosphatidyl glycerol sodium | |
CN111285899A (en) | Preparation method of di-saturated acyl phosphatidylethanolamine | |
US8569529B2 (en) | High-purity phospholipids | |
Rosenthal | [48] Chemical synthesis of phospholipids and analogues of phospholipids containing carbon-phosphorus bonds | |
EP0880530A1 (en) | Phosphatidyl oligoglycerols | |
Eibl et al. | A general synthetic method for enantiomerically pure ester and ether lysophospholipids | |
Woolley et al. | Synthesis of enantiomerically pure phospholipids including phosphatidylserine and phosphatidylglycerol | |
JPH041759B2 (en) | ||
EP0540707B1 (en) | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | |
Stewart et al. | Synthesis and characterization of deoxy analogues of diphytanylglycerol phospholipids | |
Witzke et al. | Synthesis of phosphatidylcholine analogs with an alkyl group at C1 or C3 of the glycerol moiety. | |
Baer et al. | Synthesis of propylene glycol phospholipids: analogues of α-lecithins and α-cephalins | |
CN114213458A (en) | Cyclobutylamine-terminated distearoyl phosphatidylcholine and preparation method thereof | |
Lin et al. | An efficient and novel method for the synthesis of cardiolipin and its analogs | |
EP0663918A1 (en) | Pure enantiomers of phosphoric-acid esters as phospholipase-a2 inhibitors | |
Browne et al. | On the preparation of some phospholipid analogues | |
CN117143145A (en) | Preparation method of dioleoyl phosphatidylethanolamine | |
Thompson et al. | Preparation of plasmenylcholine lipids and plasmenyl-type liposome dispersions | |
EP0581793A1 (en) | Phosphonates and phosphinates as anti-cancer, -inflammatory, -allergy and -myocarditis agents | |
Pettit et al. | Anticancer, pancratistatin, phosphate prodrugs, phosphorylation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20240322 |
|
AD01 | Patent right deemed abandoned |